Effettuare il login Iscriviti gratis

Novabay Pharmaceuticals Inc Le azioni fluttuano

Cos'è Le azioni fluttuano di Novabay Pharmaceuticals Inc?

Le azioni fluttuano di Novabay Pharmaceuticals Inc è 0.000 0.00%

Qual è la definizione di Le azioni fluttuano?

Le fluttuazione delle azioni è la parte di azioni di una società che sono nelle mani di investitori pubblici rispetto a azioni bloccate.

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

Le azioni fluttuano di aziende nel Health Care settore su NYSEMKT rispetto a Novabay Pharmaceuticals Inc

Cosa fa Novabay Pharmaceuticals Inc?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Aziende con le azioni fluttuano simili a Novabay Pharmaceuticals Inc